Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7596988 | 1.00 | ESR1 (0.49) | ESR1CYP19A1ESR2MAOBMAOA | |
| SCHEMBL7701237 | 0.83 | ESR1 (0.49) | ESR1CYP19A1ESR2 | |
| SCHEMBL7701234 | 0.83 | ESR1 (0.49) | ESR1CYP19A1ESR2 | |
| SCHEMBL23586398 | 0.80 | ESR1 (0.49) | ESR1CYP19A1ESR2CNR2 | |
| SCHEMBL7598076 | 0.76 | ESR1 (0.43) | ESR1CYP19A1ESR2NPC1RAB9A | |
| SCHEMBL7600262 | 0.76 | ESR1 (0.61) | ESR1CYP19A1ESR2NPC1RAB9A | |
| SCHEMBL7600265 | 0.76 | ESR1 (0.61) | ESR1CYP19A1ESR2NPC1RAB9A | |
| SCHEMBL7598079 | 0.76 | ESR1 (0.43) | ESR1CYP19A1ESR2NPC1RAB9A | |
| SCHEMBL11787805 | 0.75 | ESR1 (0.52) | ESR1CYP19A1ESR2 | |
| SCHEMBL7598606 | 0.75 | ESR1 (0.60) | ESR1CYP19A1ESR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | ESRRB, ESR2, ESRRG | ESR1 6/4885CYP19A1 13/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.